Inhibitors of phosphodiesterase-4 (PDE4) are efficacious for allergic asthma in animal models and have shown some efficacy in human asthma. Regulation of PDE4 in allergy and asthma has been widely investigated in blood leukocytes with discrepant results. In this study, we investigated PDE4 regulation in the lung in a rat model of allergic asthma.
-3 -Phosphodiesterase (PDE) superfamily comprises eleven biochemically and pharmacologically distinct enzyme families (PDEs 1-11) that hydrolyze cAMP and/or cGMP. PDEs represent the only cellular pathways for the degradation of the ubiquitous intracellular second messengers, underscoring their critical role in regulation of cellular functions (1) (2) (3) (4) (5) (6) . Most PDE families contain multiple genes (subtypes), and most of these genes give rise to multiple variants by alternative splicing among the 5'-end exons and/or the use of different transcription initiation sites. Despite the large number of PDE enzymes with distinct biochemical and pharmacological properties, they share some structural features. In particular, they contain a conserved catalytic domain of about 270-300 amino acids located toward the C-termini.
PDE4 is specific for cAMP and comprises four subtypes (A, B, C and D). It is
predominantly expressed and plays an important role in regulation of cellular functions in inflammatory and immune cells. There has been significant interest in PDE4 inhibitors as a potential therapy for inflammatory diseases such as allergy and asthma. In fact, PDE4 inhibitors have exhibited efficacy for asthma, allergic rhinitis and several other diseases in the clinic (7, 8) .
Regulation of PDE4 in allergy and asthma has been widely investigated in human blood leukocytes. Interleukin (IL)-4 plays a crucial role in allergic airway diseases including asthma (9) (10) (11) . Interestingly, IL-4 significantly increased PDE4 activity in human monocytes (12) . However, whether or not PDE4 is upregulated in blood leukocytes in asthma and/or allergy remains controversial. Some investigators reported a significant increase in PDE4 activity in asthmatic or allergic patients as compared to healthy individuals (13) (14) (15) (16) (17) . It is noteworthy that, when there was an increase in PDE4 -4 -activity, the increase was correlated with an increased IL-4 production (18) . However, others observed no significant change of PDE4 activity in such patients (19) (20) (21) (22) . There has been no reported study on PDE4 regulation in the lung in any animal model of asthma or in asthmatic patients.
In this study, lung PDE4 regulation was investigated in an antigen challenged rat model. In our model, there were significantly increased pulmonary resistance and lung IL-4 production. The increases in pulmonary resistance and IL-4 production were both suppressed by the PDE4-selective inhibitor rolipram or the corticosteroid drug dexamethasone. Interestingly, in the lung there was also a significant increase in cAMP-PDE enzyme activity as well as increases in PDE4 subtype mRNAs. Our data suggest, for the first time, that PDE4 may be upregulated in the lung and play a role in the pathogenesis of allergic asthma. Rats were sensitized with subcutaneous injection (1 ml) of a saline suspension 
Materials and Methods

Measurement of lung functions
Tracheostomy was performed under urethane anesthesia (1 g/kg, injected intraperitoneally).
The rat was then placed in a whole body plethysmograph, and lung functions were measured as described previously (23) .
Assay for cAMP-PDE activity
Frozen lungs were thawed and cut into small cubes. Twenty-five mg of lung tissues was homogenized in 100 µl of ice-cold 30 mM HEPES (pH 7.4) containing 0.1% Trion X-100. 
Quantification of lung IL-4
Lungs were homogenized at a ratio of 1 g/10 ml in 50 mM potassium phosphate buffer (pH 6.0) containing 0.05% NaN 3 and 0.1% CHARPS. The homogenates were centrifuged twice at 19,851 ×g, each for 30 min. IL-4 in the supernatants was quantified using a rat IL-4-specific ELISA kit (Jingmei BioTech, Shenzhen, China).
Assay for total protein
Total protein amounts were determined by the Bradford method (24) using BSA as standard.
RNA isolation and cDNA synthesis
Total RNA was isolated from each tissue using TRIzol Reagent (Invitrogen, Carlsbad, CA), Preparation of first-strand cDNA from rat and human total RNA was performed using 
Semi-quantitative RT-PCR analysis for rat PDE4 subtype mRNAs
Sequences of PCR primer sets used for PDE 4A, 4B, 4D (25) and 4C (26) electrophoresis on a 1.5% agarose gel containing ethidium bromide, and the PCR product bands were quantified by using UVP Gel Documentation system (UVP, Upland, CA).
The levels of PDE4 mRNAs were calculated relative to -actin. It was confirmed that under these conditions the PCR product accumulation did not reach plateau levels (data not shown).
Measurement of tracheal tissue contraction and relaxation
Trachea free of connective tissue was isolated in oxygenated Krebs-Henseleit buffer.
Each trachea was cut into six 1-cm long sections without damages to the epithelium. Technology, Nanjing, China). After the mechacholine-induced pre-contraction reached a plateau level, salbutamol (Sigma) was added to obtain a cumulative concentration-response curve. 
Statistical analysis
Results
Antigen-induced changes of lung function in allergic rats
In our rat model of allergic asthma, OVA sensitization caused a significant decrease in dynamic lung compliance (Cdyn) ( Cdyn and R L were significantly improved.
Antigen-induced IL-4 production in the lung of allergic rats
Because IL-4 plays a critical role in the pathogenesis of allergic airway diseases including asthma (9-11), IL-4 levels in the lungs of rats from the various groups were measured ( Fig.   -9 - 2). OVA sensitization did not increase IL-4 production. However, OVA sensitization and challenge significantly increased IL-4 production. The 7-day treatment, once a day, with rolipram at 0.1, 0.3 or 1 mg/kg or with dexamethasone at 0.1 or 0.5 mg/kg completely suppressed the increased IL-4 production, and, furthermore, gave rise to IL-4 levels lower than that of normal animals.
Allergen-induced cAMP-PDE activity elevation in the lung of allergic rats
With regard to PDE4 regulation in the lung tissues, OVA sensitization and challenge significantly elevated the lung cAMP-PDE activity, resulting in a level 2.5-fold higher than that of normal animals (Fig. 3) . Rolipram (100 µM)-sensitive cAMP-PDE activity (that is, PDE4 activity) was about 2-fold higher in OVA-sensitized and challenged rats than in normal rats. PDE3 is another cAMP-PDE known to play a role in the regulation of airway contraction (27) . However, relative PDE3 activity (determined as the activity sensitive to the PDE3-selective inhibitor siguazodan) in total cAMP-PDE activity was conversely lower in OVA-sensitized and challenged rats than in normal rats (Fig. 4) . PDE5, a cGMP-specific PDE, is also abundantly present in lung (1, 4, 6) . However, the PDE5-selective inhibitor zaprinast did not significantly affect the cAMP-PDE activity in either normal or OVA-sensitized and challenged rats. These results suggest that the increase in total cAMP-PDE activity by OVA sensitization and challenge might be primarily due to upregulation of PDE4. Interestingly, like IL-4 production, the elevation of cAMP-PDE activity was also suppressed by the 7-day treatment with rolipram or dexamethasone. The inhibition by rolipram was dose-dependent, with an ED 50 of about 0.1 mg/kg.
Since in the lung of allergic rats both cAMP-PDE activity and IL-4 levels were -10 -increased, we examined the correlation between the levels of these two biologically important proteins. By multi-variate analysis, a highly significant (p<0.01) correlation was observed (correlation coefficient: r = 0.563) (Fig. 5) .
Allergen-induced PDE4 mRNA elevation in the lung of allergic rats
To investigate if or not the cAMP-PDE activity elevation was due to enhanced PDE4 gene expression, we examined lung mRNA levels of various PDE4 subtypes in normal and allergic rats. As shown in Fig. 6 , OVA sensitization and challenge significantly increased the levels of PDE 4A, 4C and 4D mRNAs, as compared with normal rats (p<0.05 or <0.01).
This result strongly suggests that the increased cAMP-PDE activity (Fig. 3) might be, at least in part, due to enhanced PDE4 gene expression by antigen sensitization and challenge.
Allergen-induced increase in ex vivo tracheal tension
Tracheal tissues from OVA-sensitized and challenged rats had significantly increased tensions as compared with those from normal rats upon stimulation with methacholine (0.01 µM -1 mM) (Fig. 7A) . Salbutamol reversed the methacholine-induced contraction in a concentration-dependent manner.
There was an increased relaxation of methacholine-induced contraction by salbutamol in normal tracheal tissues as compared with tracheal tissues from OVA-sensitized and challenged rats (Fig. 7B ).
Discussion
Regulation of PDE4 in allergy and asthma has been investigated by many groups but only in human blood leukocytes, and the data have been discrepant. Thus, some groups have observed a significant increase in PDE4 activity in asthmatic or allergic patients (13) (14) (15) (16) (17) , whereas others have found no significant change of the enzyme activity in such The upregulation of PDE4 mRNAs demonstrates that the increased lung cAMP-PDE activity was, at least in part, due to increased PDE4 gene expression. However, nothing is known about the mechanism for the upregulated PDE4 gene expression. Nor is known why expression of various PDE4 subtype genes was regulated differentially in the lung of allergic rats, although it is known that different PDE4 subtype genes can undergo distinct regulation (28) . It is well-established that cAMP induces expression of various PDE4
subtype genes including 4B (2) . The only other significant PDE4 gene inducer known thus far is lipopolysaccharide, which specifically activates PDE4B gene in momocytes/macrophages (28, 29) . Rolipram might be expected to enhance, but not prevent (as observed in this study), the upregulation of PDE4 by increasing cAMP levels.
- 12 - In fact, upregulation of PDE4 has been reported in vivo in rats treated chronically with the effective cAMP-elevating agent albuterol (30) . However, in the lung of allergic rats, expression of PDE 4A, 4C and 4D genes, but not 4B gene, was upregulated, suggesting that the expression of the genes might be induced by a mechanism(s) distinct from the cAMP or lipopolysaccharide mechanism. Thus, rolipram might prevent the PDE4 upregulation by a secondary mechanism(s) (discussed below). Interestingly, in a cigarette smoking-induced mouse model of chronic obstructive pulmonary disease, which shares several important pathophysiological features with asthma, increased PDE4D gene expression in the lung was observed (31).
It is well-known that PDE4 also undergoes activation by phosphorylation (2, 5).
PDE4 was activated by IL-4 (12), interferon-(12), IL-3 (32) or IL-2 (14)
, presumably by post-translational modification such as phosphorylation. All these cytokines are induced at significant levels in the lungs of allergic animals (33, 34) . It is conceivable that in our model the increased lung cAMP-PDE activity could also be due in part to PDE4 activation by various cytokines. Although it is not clear exactly how dexamethasone or rolipram attenuated the PDE4 enzyme activity upregulation, one possibility for both the drugs was that they might attenuate PDE4 gene expression and/or activation through their extensive anti-inflammatory effects. For instance, corticosteroid drugs (35) and PDE4 inhibitors (27) inhibit production of the various cytokines, which could result in the downregulation of PDE4 activity observed in this study. Dexamethasone also might directly inhibit PDE4 gene expression as suggested by a very recent report (36) . However, the possibility that ex vivo PDE4 inhibition by residual rolipram in lung tissue also contributed to the observed cAMP-PDE attenuation by rolipram treatment (Fig. 3) can not be completely ruled out. PDE3 and PDE4 activities were determined as siguazodan-and rolipram-sensitive activity, respectively (both at 100 µM). *: p<0.05 vs. normal rats (n=3-5).
-21 - mRNA levels were measured by semi-quantitative RT-PCR. It was confirmed that under our conditions the PCR product accumulation did not reach plateau levels (data not shown).
After PCR, the products were resolved by agarose gel electrophoresis and then quantified by image analysis. The data shown are expressed relative to -actin. *: p<0.05; ** p<0.01 (vs. normal rats). 
